Bordetella vaccines comprising LPS with reduced reactogenicity
The current invention lies in the field of medicine and more specifically in the field of vaccinology. The current invention concerns a novel Bordetella LPS and a modified bacterium of the genus Bordetella comprising such modified LPS. The LPS of the invention has a reduced endotoxicity in comparison to an unmodified Bordetella LPS. The modified LPS of the invention is therefore particularly suitable for use in inducing or stimulating an immune response in a subject, wherein the immune response is induced or stimulated against a Bordetella infection. The modified Bordetella LPS of the invention is obtainable by introducing in a Bordetella cell the expression of a heterologous acyl transferase. In particular, the modified Bordetella cell of the invention has an increased expression of an heterologous LpxA, LpxL or LpxD acyl transferase.
1. A genetically modified Bordetella pertussis, Bordetella parapertussis or Bordetella bronchiseptica bacterium,
wherein the bacterium is modified compared to the wild-type Bordetella pertussis, Bordetella parapertussis or Bordetella bronchiseptica bacterium in that it has a genetic modification that introduces a heterologous acyl transferase activity,
wherein the genetic modification that introduces heterologous acyl transferase activity confers to the cell at least one of a heterologous LpxA, LpxL and LpxD acyl transferase activity and wherein the genetic modification introduces the expression of at least one of a heterologous LpxA, a LpxL, and a LpxD acyl transferase, wherein
i) the LpxA acyl transferase has SEQ ID NO: 1, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 1;
ii) the LpxL acyl transferase has SEQ ID NO: 2, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 2; and/or
iii) the LpxD acyl transferase has SEQ ID NO: 4, or a variant thereof having at least 95% amino acid sequence identity with SEQ ID NO. 4,
wherein expression of the heterologous acyl transferase results in a B. pertussis, B. parapertussis or B. bronchiseptica LPS having a lipid A moiety that is modified as compared to the lipid A moiety of a wild-type B. pertussis, B. parapertussis or B. bronchiseptica LPS in that the length of at least one acyl chain is shorter and wherein the length of the acyl chain at the 3 position of the modified lipid A moiety does not have a greater length than the acyl chain of the wild-type B. pertussis, B. parapertussis or B. bronchiseptica lipid A moiety at the same 3 position.
2. The genetically modified bacterium according to claim 1 , wherein the bacterium is modified compared to the wild-type B. pertussis, B. parapertussis or B. bronchiseptica bacterium in that it has a genetic modification that introduces a heterologous UDP-2,3-diacylglucosamine pyrophosphatase activity.
3. The genetically modified bacterium according to claim 2 , wherein the genetic modification introduces the expression of a heterologous lpxH UDP-2,3-diacylglucosamine pyrophosphatase, and wherein the LpxH UDP-2,3-diacylglucosamine pyrophosphatase has at least 95% sequence identity with SEQ ID NO: 5.
4. The genetically modified bacterium according to claim 3 , wherein the lpxH UDP-2,3-diacylglucosamine pyrophosphatase has SEQ ID NO: 5.
5. Bordetella LPS, wherein the LPS is obtainable from a genetically modified B. pertussis, B. parapertussis or B. bronchiseptica bacterium according to claim 1 .
6. The Bordetella LPS according to claim 5 , wherein at least 70% of the LPS has a modified lipid A moiety, wherein the lipid A moiety is modified as compared to the lipid A moiety of a wild-type Bordetella pertussis, Bordetella parapertussis or Bordetella bronchiseptica LPS in that the length of at least one acyl chain is shorter, and wherein the shorter acyl chain selected from the group consisting of:
i) the acyl chain at the 3′ position of the lipid A moiety is C10;
ii) the primary acyl chain at the 2′ position of the lipid A moiety is C12;
iii) the secondary acyl chain at the 2′ position of the lipid A moiety is C12; and
iv) the acyl chain at the 2 position of the Lipid A moiety is C12, and
wherein the length of the acyl chain at the 3 position of the modified lipid A moiety does not have a greater length than the acyl chain of the wild-type Bordetella lipid A moiety at the same 3 position.
7. The Bordetella LPS according to claim 6 , wherein the length of the acyl chain at the 3 position of the modified lipid A moiety is not greater than C10.
8. The Bordetella LPS according to claim 7 , wherein the length of the acyl chain at the 3 position of the modified lipid A moiety has the same length as the acyl chain of the wild-type Bordetella lipid A moiety at the same 3 position.
9. The Bordetella LPS according to claim 8 , wherein the length of the acyl chain at the 3 position is C10.
10. An OMV obtainable from the genetically modified bacterium as defined in claim 1 .
11. A composition comprising at least one of:
Bordetella LPS obtainable from a genetically modified bacterium according to claim 1 ;
a genetically modified bacterium of claim 1 ; and
an OMV obtainable from the genetically modified bacterium of claim 1 , wherein optionally the composition is a pharmaceutical composition further comprising a pharmaceutically accepted excipient.
12. The composition according to claim 11 , wherein the genetically modified bacterium is inactivated.
13. The composition according to claim 11 , wherein the composition further comprises at least one non- Bordetella antigen.
14. The genetically modified bacterium according to claim 1 , wherein the bacterium is a genetically modified Bordetella pertussis.
15. The genetically modified bacterium according to claim 14 , wherein the bacterium is a genetically modified Bordetella pertussis B213 strain.
16. The genetically modified bacterium according to claim 1 , wherein the bacterium has a genetic modification that increases the expression of a lipid A 3-O-deacylase, and wherein the lipid A 3-O-deacylase has at least 95% sequence identity with SEQ ID NO: 25.
17. The genetically modified bacterium according to claim 1 , wherein the modified bacterium further comprises a genetic mutation that reduces or eliminates the activity and/or expression of an endogenous LpxA acyl transferase and/or an endogenous LpxD acyl transferase, wherein the endogenous LpxA acyl transferase has at least 95% sequence identity with SEQ ID NO: 28 and wherein the endogenous LpxD acyl transferase has at least 95% sequence identity with SEQ ID NO: 29.
18. The genetically modified bacterium according to claim 1 , wherein
i) the variant of the LpxA acyl transferase has at least 98% amino acid sequence identity with SEQ ID NO: 1;
ii) the variant of the LpxL acyl transferase has at least 98% amino acid sequence identity with SEQ ID NO: 2; and/or
iii) the variant of the LpxD acyl transferase has at least amino acid sequence identity with SEQ ID NO: 4.
19. The genetically modified bacterium according to claim 1 , wherein
i) the LpxA acyl transferase is SEQ ID NO: 1;
ii) the LpxL acyl transferase is SEQ ID NO: 2; and/or
iii) the LpxD acyl transferase is SEQ ID NO: 4.
20. The genetically modified bacterium according to claim 1 , wherein
i) the variant of the LpxA acyl transferase is a heterologous LpxA acyl transferase obtained from a Gram negative bacterium;
ii) the variant of the LpxL acyl transferase is a heterologous LpxL acyl transferase obtained from a Gram negative bacterium; and
iii) the variant of the LpxD acyl transferase is a heterologous LpxD acyl transferase obtained from a Gram negative bacterium.
21. A method for inducing or stimulating an immune response in a subject in need thereof, comprising administering to the subject the composition of claim 11 , wherein the immune response is stimulated or induced against a Bordetella infection.
22. The method of claim 21 , wherein the subject in need thereof suffers from whooping cough.
23. The method of claim 21 , wherein the Bordetella infection is a Bordetella pertussis infection.